Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Tcheng
James E
JE
Campbell
Mark E
ME
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D013988:Ticlopidine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077144:Clopidogrel; D000077466:Tirofiban; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab